Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) have earned a consensus rating of “Hold” from the six analysts that are covering the stock, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $11.80.
A number of equities analysts have recently weighed in on IRWD shares. Morgan Stanley upped their price objective on Ironwood Pharmaceuticals from $11.00 to $12.00 and gave the stock an “equal weight” rating in a research note on Friday, July 16th. Northland Securities reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Ironwood Pharmaceuticals in a research note on Tuesday, July 6th.
Large investors have recently bought and sold shares of the company. Captrust Financial Advisors lifted its stake in shares of Ironwood Pharmaceuticals by 7,057.7% in the 1st quarter. Captrust Financial Advisors now owns 3,722 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 3,670 shares during the last quarter. Royal Bank of Canada lifted its stake in shares of Ironwood Pharmaceuticals by 127.2% in the 1st quarter. Royal Bank of Canada now owns 4,221 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 2,363 shares during the last quarter. Amundi Pioneer Asset Management Inc. bought a new stake in shares of Ironwood Pharmaceuticals in the 1st quarter valued at approximately $63,000. Pinz Capital Management LP bought a new stake in shares of Ironwood Pharmaceuticals in the 2nd quarter valued at approximately $116,000. Finally, E Fund Management Co. Ltd. bought a new stake in shares of Ironwood Pharmaceuticals in the 1st quarter valued at approximately $137,000.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its quarterly earnings data on Thursday, August 5th. The biotechnology company reported $0.34 earnings per share for the quarter, topping analysts’ consensus estimates of $0.23 by $0.11. The firm had revenue of $104.00 million during the quarter, compared to analyst estimates of $92.47 million. Ironwood Pharmaceuticals had a return on equity of 109.74% and a net margin of 123.20%. The business’s quarterly revenue was up 16.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.16 earnings per share. On average, equities research analysts predict that Ironwood Pharmaceuticals will post 1.18 EPS for the current year.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, Inc is a healthcare company, which focuses on the development and commercialization of Gastrointestinal (GI) product opportunities in areas of significant unmet need, leveraging demonstrated expertise and capabilities in GI diseases. Its products include linaclotide, a guanylate cyclase type-C agonists which treats patients irritable bowel syndrome with constipation and chronic constipation.
Featured Story: What are the advantages of the Stochastic Momentum Index?
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.